🔴 SAB Biotherapeutics is trading 5% down today amid a biotech-sector sell-off

SAB Biotherapeutics is trading at $3.02, down 5.03% now, alongside a sharp biotech-sector decline; broad risk-off pressure is the clearest context.

• The XBI is down 5.19% during the regular session.
• In Q3 results reported November 5, the company posted a $22.3 million net loss versus $45.4 million net income a year earlier, while highlighting $205.3 million in cash and runway through 2028. The release did not establish that results caused the drop.